MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.

Authors	SVOBODA Marek ŠÁNA Jiří RÉDOVÁ Martina NAVRÁTIL Jiří PALÁCOVÁ Markéta FABIAN Pavel SLABÝ Ondřej VYZULA Rostislav
Year of publication	2012
Type	Article in Periodical
Magazine / Source	Diagnostic Pathology
MU Faculty or unit	Faculty of Medicine
Citation
Web	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349474/?tool=pubmed
Doi	http://dx.doi.org/10.1186/1746-1596-7-31
Field	Oncology and hematology
Keywords	triple-negative breast cancer; miR-34a; miR-34b; miR-34c; prognosis
Description	Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast cancer, characterized by higher incidence in young women and a very poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs playing significant role in the pathogenesis of many cancers including breast cancer. Therefore, miRNAs are also potential prognostic and/or predictive biomarkers in triple-negative breast cancer patients.